INT103806

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.41
First Reported 2002
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 4
Total Number 4
Disease Relevance 3.72
Pain Relevance 0.31

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

Anatomy Link Frequency
superior 1
uterine 1
Aaiq4 (Mus musculus)
Pain Link Frequency Relevance Heat
endometriosis 5 93.32 High High
pain pelvic 1 88.24 High High
agonist 8 64.96 Quite High
Peripheral nervous system 1 55.20 Quite High
Pain 4 5.00 Very Low Very Low Very Low
imagery 3 5.00 Very Low Very Low Very Low
palliative 2 5.00 Very Low Very Low Very Low
ketamine 2 5.00 Very Low Very Low Very Low
chemokine 2 5.00 Very Low Very Low Very Low
antagonist 2 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Endometriosis (extended) 7 99.60 Very High Very High Very High
Cancer 141 99.56 Very High Very High Very High
Breast Cancer 58 99.24 Very High Very High Very High
Weight Gain 4 97.92 Very High Very High Very High
Obesity 133 96.84 Very High Very High Very High
Metastasis 108 95.12 Very High Very High Very High
Apoptosis 6 90.88 High High
Reprotox - General 3 2 88.24 High High
Death 6 87.72 High High
Recurrence 9 87.48 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Genetic or enzymatic disruption of aromatase inhibits the growth of ectopic uterine tissue.
Negative_regulation (disruption) of aromatase in uterine
1) Confidence 0.41 Published 2002 Journal J. Clin. Endocrinol. Metab. Section Title Doc Link 12107266 Disease Relevance 0.57 Pain Relevance 0.25
Aromatase deficiency, during which E2 is not produced, results in the development of adiposity and obesity [66].
Negative_regulation (deficiency) of Aromatase associated with obesity
2) Confidence 0.02 Published 2010 Journal PPAR Research Section Body Doc Link PMC2943125 Disease Relevance 1.37 Pain Relevance 0.03
Unlike most current cancer therapies, including aromatase inhibitors, which cause bone loss [67], 2ME2 and SD-208 have bone-sparing effects that may contribute the beneficial effect on bone metastases [60], [68].
Negative_regulation (inhibitors) of aromatase associated with cancer and metastasis
3) Confidence 0.01 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2731927 Disease Relevance 1.06 Pain Relevance 0
Available clinical evidence, although limited, suggests that the response to aromatase inhibitors in HER-2 positive breast cancers is superior to tamoxifen.
Negative_regulation (inhibitors) of aromatase in superior associated with breast cancer
4) Confidence 0.01 Published 2008 Journal Int Semin Surg Oncol Section Body Doc Link PMC2383915 Disease Relevance 0.71 Pain Relevance 0.03

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox